Cargando…
Treating COPD with PDE 4 inhibitors
While the pathogenesis of chronic obstructive pulmonary disease (COPD) is incompletely understood, chronic inflammation is a major factor. In fact, the inflammatory response is abnormal, with CD8(+) T-cells, CD68(+) macrophages, and neutrophils predominating in the conducting airways, lung parenchym...
Autor principal: | Brown, William M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699952/ https://www.ncbi.nlm.nih.gov/pubmed/18268925 |
Ejemplares similares
-
Evaluation of PDE4 inhibition for COPD
por: Wang, Desuo, et al.
Publicado: (2006) -
Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014) -
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007) -
The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD
por: Williams, Dennis
Publicado: (2020) -
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
por: Singh, Dave, et al.
Publicado: (2019)